Liraglutide (Hangzhou Heze Pharma)

利拉鲁肽（浙江和泽医药）

Report date: 2025/10/27 13:35:07

Base Information

Drug NameLiraglutide (Hangzhou Heze Pharma)
Drug Alias NameN/A
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHangzhou Heze Pharmaceutical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Heze Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A